Suppr超能文献

柠檬酸铁用于治疗非透析慢性肾脏病患者的高磷血症和缺铁性贫血:一项系统评价和荟萃分析。

Ferric citrate for the treatment of hyperphosphatemia and iron deficiency anaemia in patients with NDD-CKD: a systematic review and meta-analysis.

作者信息

Ding Xueying, Sun Shujie, Zhang Jinjin, Zhao Huifang, Lun Fenglan, Liu Xuemin, Zhen Yiwan, Dong Jinping, Wu Jingliang

机构信息

Medical College, Weifang University of Science and Technology, Weifang, China.

出版信息

Front Pharmacol. 2024 Mar 7;15:1285012. doi: 10.3389/fphar.2024.1285012. eCollection 2024.

Abstract

The application of ferric citrate therapy has yielded unexpected benefits in recent years for Chronic kidney disease patients suffering from hyperphosphatemia and iron deficiency -anaemia. Despite this, earlier research on the impact of ferric citrate on NDD-CKD has been contentious. The goal of the meta-analysis is to evaluate the evidence regarding the advantages and dangers of ferric citrate for the treatment of hyperphosphatemia and iron deficiency anaemia in NDD-CKD patients. Between the start of the study and June 2022, we searched PubMed, Embase, Cochrane, EBSCO, Scopus, Web of Science, Wan Fang Data, CNKI, and VIP databases for randomised controlled trials of iron citrate for hyperphosphatemia and anaemia in patients with NDD-CKD. For binary categorical data, risk ratios (OR) were employed, and for continuous variables, weighted mean differences The effect sizes for both count and measurement data were expressed using 95% confidence intervals The meta-analysis includes eight trials with a total of 1281 NDD-CKD patients. The phosphorus-lowering effect of ferric citrate was greater compared to the control group (WMD, -0.55, 95% CI, -0.81 to -0.28; I = 86%, < 0.001). Calcium (WMD, 0.092; 95% CI, -0.051 to 0.234; > 0.05; I = 61.9%), PTH (WMD, -0.10; 95% CI, -0.44 to 0.23; I = 75%, > 0.05) and iFGF23 (WMD, -7.62; 95% CI, -21.18 to 5.94; I = 20%, > 0.05) levels were not statistically different after ferric citrate treatment compared to control treatment. Furthermore, ferric citrate increased iron reserves and haemoglobin. The ferric citrate group had considerably greater levels than the controls. Ferric citrate, on the other hand, may raise the risk of constipation, diarrhoea, and nausea. This meta-analysis found that ferric citrate had a beneficial effect in the treatment of NDD-CKD, particularly in reducing blood phosphorus levels when compared to a control intervention. It also shown that ferric citrate has a favourable effect on iron intake and anaemia management. In terms of safety, ferric citrate may increase the likelihood of gastrointestinal side effects.

摘要

近年来,柠檬酸铁疗法给患有高磷血症和缺铁性贫血的慢性肾脏病患者带来了意想不到的益处。尽管如此,早期关于柠檬酸铁对非透析慢性肾脏病影响的研究一直存在争议。本荟萃分析的目的是评估关于柠檬酸铁治疗非透析慢性肾脏病患者高磷血症和缺铁性贫血的益处和风险的证据。在研究开始至2022年6月期间,我们检索了PubMed、Embase、Cochrane、EBSCO、Scopus、Web of Science、万方数据、中国知网和维普数据库,以查找关于柠檬酸铁治疗非透析慢性肾脏病患者高磷血症和贫血的随机对照试验。对于二元分类数据,采用风险比(OR),对于连续变量,采用加权平均差。计数和测量数据的效应量均用95%置信区间表示。该荟萃分析纳入了8项试验,共1281例非透析慢性肾脏病患者。与对照组相比,柠檬酸铁的降磷效果更佳(加权平均差,-0.55;95%置信区间,-0.81至-0.28;I² = 86%,P < 0.001)。柠檬酸铁治疗后,钙(加权平均差,0.092;95%置信区间,-0.051至0.234;P > 0.05;I² = 61.9%)、甲状旁腺激素(加权平均差,-0.10;95%置信区间,-0.44至0.23;I² = 75%,P > 0.05)和全段成纤维细胞生长因子23(加权平均差,-7.62;95%置信区间,-21.18至5.94;I² = 20%,P > 0.05)水平与对照治疗相比无统计学差异。此外,柠檬酸铁增加了铁储备和血红蛋白。柠檬酸铁组的水平显著高于对照组。另一方面,柠檬酸铁可能会增加便秘、腹泻和恶心的风险。该荟萃分析发现,柠檬酸铁在治疗非透析慢性肾脏病方面具有有益作用,特别是与对照干预相比,能降低血磷水平。研究还表明,柠檬酸铁对铁摄入和贫血管理有积极作用。在安全性方面,柠檬酸铁可能会增加胃肠道副作用的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bdc/10955115/9762aa174c67/fphar-15-1285012-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验